Spring Bank Pharmaceuticals

General Information

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. Our SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. We are developing our most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. We have designed SB 9200 to selectively activate within infected cells the cellular proteins retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense.

Employees: 17
Founded: 2002
Contact Information
Address 113 Cedar Street, Milford, MA 01757, US
Phone Number (508) 473-5993
Web Address http://www.springbankpharm.com
View Prospectus: Spring Bank Pharmaceuticals
Financial Information
Market Cap $85.1mil
Revenues $0.9 mil (last 12 months)
Net Income $-11.6 mil (last 12 months)
IPO Profile
Symbol SBPH
Exchange NASDAQ
Shares (millions): 0.9
Price range $12.00 - $12.00
Est. $ Volume $11.0 mil
Manager / Joint Managers Dawson James Securities
CO-Managers -
Expected To Trade: 5/6/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change